<DOC>
	<DOCNO>NCT02574858</DOCNO>
	<brief_summary>The purpose study evaluate safety orally administer QRH-882260 , topically administer Cy5-labeled heptapeptide specific epithelial growth factor receptor ( EGFR ) .</brief_summary>
	<brief_title>Study Safety QRH-882260 Heptapeptide</brief_title>
	<detailed_description>This Phase IA study safety orally administer QRH-882260 heptapeptide detection neoplastic tissue multiple area gastrointestinal tract human . The investigator intend enroll 10 evaluable subject . The investigator expect able enroll 1-2 subject per week , study take 1-2 month complete . Interested , healthy subject age 25-100 respond recruitment advertising appear eligible base screen questionnaire schedule study visit MCRU . At study visit , subject review sign inform consent eligibility confirm . If eligible , subject provide blood sample clinical lab urine sample urinalysis . A baseline EKG record . A negative urine pregnancy test woman child-bearing potential require eligible . Eligible subject consume reconstitute QRH-882260 heptapeptide . After 5 minute , subject drink minimum 4-8 ounce tap water . Subjects remain MCRU observation 30 minute . Vital sign EKG record 30 minute . Subjects require repeat blood draw clinical lab urinalysis within 24 48 hour QRH-882260 heptapeptide ingestion . The study team conduct follow phone call verbally assess toxicity post-ingestion lab ( within 7 day ) .</detailed_description>
	<criteria>Inclusion Criteria Adults age 25 100 year Not pregnant ( willing pregnancy test applicable ) No recent illness ( infection , URI , virus flu ) within 2 week , Stable health status ( i.e . medication change within 2 month , recent surgery , etc . per PI ) Willing able sign inform consent Willing able drink peptide tap water chaser Willing able get baseline 2448 hour post ingestion lab Exclusion Criteria Known allergy Cy5 derivative , indocyanine green ( ICG ) Subjects active chemotherapy radiation therapy Diabetics insulin/hypoglycemic ( due fasting requirement )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>